NicOx SA Attends 2012 American Academy of Ophthalmology Meeting in Chicago
Published: Nov 09, 2012
SOPHIA ANTIPOLIS CEDEX, FRANCE--(Marketwire - November 09, 2012) - Nicox S.A. (EURONEXT PARIS: COX) is attending the American Academy of Ophthalmology (AAO) & Asia Pacific Academy of Ophthalmology (APAO) 2012 Joint Meeting, taking place from November 10 to 13 in Chicago, Illinois, United States (US). Nicox can be found at booth number 2735.
Nicox's US operational team, including Jerry St. Peter, Executive Vice President (EVP) and General Manager of Nicox Inc, will present AdenoPlus™, a rapid point-of-care diagnostic test that aids in the differential diagnosis of acute conjunctivitis. AdenoPlus™ was launched by Nicox in the US in October 2012 (see Nicox press release dated October 22, 2012).
Michele Garufi, Chairman and CEO, Gavin Spencer, EVP Corporate Development and Philippe Masquida, EVP, Managing Director of European & International Operations will also attend the meeting.
Nicox's goal is to become a new international player in the ophthalmic market by building a diversified portfolio of innovative therapies and diagnostic tools.
Nicox (Bloomberg: COX:FP, Reuters: NCOX.PA) is creating a new international player in the ophthalmic market by building a diversified portfolio of innovative therapies and diagnostic tools. With a heritage of scientific, business development and commercial expertise, strengthened by internal research capabilities, Nicox is focused on developing and marketing novel pharmaceuticals and diagnostics that can help people to enhance their sight. In the United States, Nicox markets AdenoPlus™, a test for the differential diagnosis of acute conjunctivitis in-licensed from RPS®, to eyecare practitioners.
The Company's pipeline includes BOL-303259-X, a novel drug-candidate based on Nicox's proprietary nitric oxide (NO)-donating R&D platform, developed in collaboration with Bausch + Lomb for the potential treatment of glaucoma and ocular hypertension. Further NO-donating compounds are under development in non-ophthalmic indications, notably through partners, including Merck (known as MSD outside the United States and Canada) and Ferrer.
Nicox S.A. is headquartered in France and is listed on Euronext Paris (Compartment C: Small Caps). For more information please visit www.nicox.com.
Nicox S.A. Les Taissounières | Bât HB4 | 1681 route des Dolines | BP313 | 06906 Sophia Antipolis Cedex | France T: +33 (0)4 97 24 53 00 | F: +33 (0)4 97 24 53 99
Nicox attends 2012 AAO Meeting in Chicago: http://hugin.info/143509/R/1656395/535518.pdf
This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: NICOX via Thomson Reuters ONE
Executive Vice President Corporate Development
Tel +33 (0)4 97 24 53 00
D+44 (0) 20 7269 7205
M +44 (0) 7515 597 858
D +44 (0) 20 3077 0458
M +44 (0) 7843 080947